Myeloproliferative Neoplasms (MPN)

- **CNL/atypical CML**
  - IRB# 10262
  - Oral Ruxolitinib for CNL or atypical CML

- **Myelofibrosis**
  - IRB# 16363
  - Phase 2 INC0050465 plus Ruxolitinib
  - IRB# 15836
  - Dual Syk/Jak inhibitor for myelofibrosis with JAK2 mutation

- **Systemic Mastocytosis**
  - IRB# 17899
  - Study Coming Soon

- **Non Treatment National MDS Study (ECOG/ACRIN)**
  - IRB# 15977
  - Oral Ruxolitinib for CNL or atypical CML

Additional information:
- http://www.ohsu.edu/research/rda/so/knight.php
- Key:
  - Open for Enrollment
  - In Development
  - Enrollment on Hold